Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02501759 · ClinicalTrials.gov registry record · NA
Transrectal MRI-Guided Biopsy in Identifying Cancer in Patients With Suspected Prostate Cancer
A NA study, sponsored by OHSU Knight Cancer Institute.
- Terminated
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT02501759 is a NA study that was terminated before completion, run by OHSU Knight Cancer Institute. The registered enrollment target is 2 participants.
The verdict
NCT02501759, a NA study, was terminated before completion, sponsored by OHSU Knight Cancer Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
This pilot clinical trial studies transrectal magnetic resonance imaging (MRI)-guided biopsy to see how well it works in identifying cancer in patients with suspected prostate cancer who are scheduled to undergo standard biopsy. Transrectal MRI-guided biopsy uses a thin needle inserted through the rectum into the prostate and takes a sample of tissue, guided by MRI. MRI uses magnets to take pictures of the prostate and may be able to identify cancer. Transrectal MRI-guided biopsy may be more accurate and cause patients less pain than standard ultrasound-guided biopsy. It is not yet known whether transrectal MRI-guided biopsy is more effective than ultrasound-guided biopsy in identifying prostate cancer.
Interventions
- PROCEDURE Multiparametric Magnetic Resonance Imaging
- PROCEDURE Ultrasound-Guided Prostate Biopsy
- PROCEDURE 3 Tesla Magnetic Resonance Imaging
- RADIATION Gadodiamide
- PROCEDURE Transrectal Biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-05 |
| Est. Completion | 2017-02-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02501759
The ClinicalTrials.gov registry entry for NCT02501759 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Multiparametric Magnetic Resonance Imaging is the first listed.
NCT02501759 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02501759 about?
NCT02501759 is a clinical study titled "Transrectal MRI-Guided Biopsy in Identifying Cancer in Patients With Suspected Prostate Cancer". This pilot clinical trial studies transrectal magnetic resonance imaging (MRI)-guided biopsy to see how well it works in identifying cancer in patients with suspected prostate cancer who are scheduled to undergo standard biopsy. Transrectal MRI-guided biopsy uses a thin needle inserted through the r...
What is the current status of trial NCT02501759?
This trial is currently terminated. It is a NA study. The enrollment target is 2 participants. The study started on 2015-05. Estimated completion is 2017-02-10.
What interventions are being tested in trial NCT02501759?
The interventions under investigation include: Multiparametric Magnetic Resonance Imaging (PROCEDURE), Ultrasound-Guided Prostate Biopsy (PROCEDURE), 3 Tesla Magnetic Resonance Imaging (PROCEDURE), Gadodiamide (RADIATION), Transrectal Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT02501759?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.